PODD · Insulet Corp
Price
Snapshot
50 fields · last close| Market Cap | $9.75B |
| P/E | 25.98 |
| Float | 69.02M |
| Beta | 1.08 |
| Volatility | 27.0% |
| Exchange | NASDAQ |
| Sector | Health Care |
| Cap tier | Mid cap |
| Macro sensitivity | Moderate |
| Clavix score | 64 |
| Price | 139.29 |
| Change | −0.93% |
| Prev Close | 140.60 |
| Open | 141.25 |
| Day Low | 139.96 |
| Day High | 142.17 |
| Avg Vol | 2 |
| Avg $ Vol | $251.0M |
| 52W High | 354.88 |
| 52W Low | 126.40 |
| 52W Pos | 5.6% |
| From High | −60.75% |
| From Low | +10.20% |
| Max DD 1Y | −61.90% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −2.54% |
| SMA 50 | −7.55% |
| SMA 200 | −30.93% |
| RSI (14) | 45.2 |
| Vol 30D | 35.0% |
| Vol 90D | 55.2% |
| 1Y Range | 126–355 |
| Daily bars | 516 |
| Perf Week | +6.55% |
| Perf Month | −7.20% |
| Perf Quarter | −3.54% |
| Perf Half Y | −38.50% |
| Perf Year | −56.37% |
| Perf YTD | −50.77% |
| Prev Day | −0.93% |
| Clavix | C+ |
| Debt / Eq | 0.63 |
| Curr Ratio | 2.81 |
| Int Cover | 14.7× |
| FCF Margin | 8.7% |
| Rev Growth | +23.5% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 43 / 47 |
What PODD does
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
The company sells its products to end-users through the pharmacy channel; and independent distributors.
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Clavix risk grade
regraded every trading dayPODD grades C+, 64 of 100. Steadiest on News Sentiment (69), most exposed on Price Stability (48, fragile). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 43 of 47 in Health Care by Clavix score.
How rough the ride is
| PODD | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.08 | 0.85 |
| Volatilityannualized | 27.0% | 21.2% |
| Max drawdown, past yearworst peak-to-trough fall | −61.9% | — |
| Typical daily movemedian absolute daily change | 1.38% | — |
| Days beyond ±3%of the last 252 sessions | 4518% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| PODD | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.08 | 0.85 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate55% of 47 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| PODD | |
|---|---|
| 1 week | +6.5% |
| 1 month | −7.2% |
| Year to date | −50.8% |
| 1 year | −56.4% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| PODD | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 26 Aug |
| Average score0 most bearish, 100 most bullish | 30 |
| Bullish · bearisharticles above 60 · below 40 | 3 · 24 |
| Directionarticles whose tone is improving vs worsening | 3 ↑ 24 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 47 Health Care names Clavix covers; the tick is the sector median.
Growth
| PODD | |
|---|---|
| Revenue growthyear over year | +23.5% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openInsulet (PODD) is considering expanding its Acton, Massachusetts headquarters campus, with the state offering a record-setting $40 million-plus tax incentive package tied to creating up to 1,000 new full-time jobs by 2032. The company is evaluating a $33 million renovation of a nearby property at 35 Nagog Park to accommodate roughly 500 to 530 employees.
Insulet Corporation (PODD) reported that two long-serving board members are stepping down. Timothy J. Scannell left the board on September 3, 2026 for health reasons after 12 years of service, including 7 as Chairman. Michael R. Minogue will leave effective September 15, 2026 to run for Governor of Massachusetts, after 9 years on the board.
An analyst-style article weighs whether to keep holding Insulet (PODD), pointing to Omnipod 5 adoption, product expansion and a raised international growth outlook as positives, while flagging competitive and cost pressures. The body is a single sentence and does not report a new event or provide specific figures.
An article weighs whether to keep Insulet (PODD) stock, pointing to strong uptake of its Omnipod 5 insulin pump, ongoing product expansion, and a raised outlook for international growth as reasons to hold, while noting competitive pressure and cost challenges as concerns.
Massachusetts officials are offering a $40 million job creation package to keep Insulet Corp., a maker of automated insulin delivery systems based in Acton, MA, from relocating. The company reported $2.7 billion in revenue in 2025 and employs 5,400 people globally.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| GKOS | Glaukos Corp | B- | $9.66B | — | 0.74 | Compare |
| GMED | Globus Medical Inc | B | $9.95B | 18.58 | 1.00 | Compare |
| HSIC | Henry Schein Inc | A- | $9.46B | 23.46 | 0.87 | Compare |
| UHS | Universal Health Services Inc | A- | $10.41B | 6.82 | 1.12 | Compare |
| MOH | Molina Healthcare Inc | B | $10.48B | 22.21 | 0.73 | Compare |
| ALGN | Align Technology Inc | B- | $10.49B | 25.35 | 1.74 | Compare |
| COO | Cooper Companies Inc | B- | $10.51B | 18.44 | 0.84 | Compare |
| BTSG | Brightspring Health Services Inc | B- | $11.23B | 30.70 | 1.89 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.